We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+12.16%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$306M
AUM Growth
-$97.7M
(-24%)
Cap. Flow
-$113M
Cap. Flow
% of AUM
-36.85%
Top 10 Holdings %
Top 10 Hldgs %
75.57%
Holding
48
New
14
Increased
7
Reduced
8
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$12.7M |
| 2 |
Aldeyra Therapeutics
ALDX
|
+$9.84M |
| 3 |
Pfizer
PFE
|
+$7.88M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.57M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$5.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$26.5M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$24.7M |
| 3 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$14.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$13.7M |
| 5 |
Humana
HUM
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.22% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
1
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $52.6M | 17.22% |
1,000,000
+230,000
| +30% | +$12.4M |
|
|
2
Regeneron Pharmaceuticals
REGN
$70.9B
| $42.2M | 13.83% |
75,627
+10,922
| +17% | +$5.53M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $24.1M | 7.9% |
257,764
-35,662
| -12% | -$3.28M |
|
4
Medtronic
MDT
$106B
| $22.9M | 7.5% |
184,680
-54,964
| -23% | -$6.9M |
|
|
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
| $22.4M | 7.33% |
425,671
+25,829
| +6% | +$1.39M |
|
6
Jazz Pharmaceuticals
JAZZ
$15.5B
| $15.9M | 5.2% |
89,370
-21,012
| -19% | -$3.64M |
|
7
Protagonist Therapeutics
PTGX
$9.06B
| $15.3M | 5.02% |
341,650
+84,564
| +33% | +$2.79M |
|
|
8
Johnson & Johnson
JNJ
$609B
| $14.1M | 4.62% |
85,596
-83,038
| -49% | -$13.7M |
|
|
9
Cigna
CI
$74.5B
| $12M | 3.93% |
+50,699
| New | +$12.7M |
|
|
10
Aldeyra Therapeutics
ALDX
$102M
| $9.27M | 3.03% |
+818,025
| New | +$9.84M |
|
|
11
Pfizer
PFE
$143B
| $7.94M | 2.6% |
+202,692
| New | +$7.88M |
|
12
Evolus
EOLS
$377M
| $6.29M | 2.06% |
496,826
+415,801
| +513% | +$4.57M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.16M | 2.01% |
+150,783
| New | +$5.57M |
|
14
Celldex Therapeutics
CLDX
$2.77B
| $5.86M | 1.92% |
175,305
-21,367
| -11% | -$587K |
|
|
15
Humana
HUM
$48B
| $5M | 1.64% |
11,305
-24,388
| -68% | -$10.7M |
|
16
Edwards Lifesciences
EW
$49.4B
| $5M | 1.64% |
+48,267
| New | +$4.55M |
|
|
ENDP
17
CALL
DELISTED
Endo International plc
ENDP
| $4.91M | 1.61% |
+1,048,100
| New | +$6.01M |
|
18
CALL
Fulgent Genetics
FLGT
$573M
| $4.61M | 1.51% |
+50,000
| New | +$3.99M |
|
19
Moderna
MRNA
$24.5B
| $4.51M | 1.48% |
+19,193
| New | +$3.43M |
|
20
CALL
Teva Pharmaceuticals
TEVA
$37.3B
| $4.41M | 1.44% |
+445,900
| New | +$4.72M |
|
|
EGRX
21
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.06M | 1.33% |
+94,922
| New | +$3.92M |
|
|
MREO
22
Mereo BioPharma
MREO
$49.5M
| $3.97M | 1.3% |
+1,253,729
| New | +$4.21M |
|
|
SNCE
23
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $2.7M | 0.88% |
13,494
-1,506
| -10% | -$306K |
|
|
AVDL
24
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.11M | 0.69% |
313,795
+153,539
| +96% | +$1.22M |
|
25
argenx
ARGX
$53.8B
| $1.93M | 0.63% |
+6,408
| New | +$1.82M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Tri Locum Partners held 48 positions worth $306M, down 24% from $403M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Tri Locum Partners withdrew a net $113M in Q2 2021, closing 19 positions and reducing 8 holdings. Its most notable exit was Baxter International, an estimated $26.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 72% a quarter earlier, followed by Technology.
Against the trend, Tri Locum Partners opened a new position in Cigna worth $12M.
- Tri Locum Partners's largest Q2 2021 buy was Cigna: 50,699 shares worth $12M.
- Tri Locum Partners added most to Regeneron Pharmaceuticals in Q2 2021, an estimated $5.53M increase.
- Tri Locum Partners's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $13.7M.
- Tri Locum Partners fully exited Baxter International in Q2 2021, selling an estimated $26.5M.
- Tri Locum Partners's ten largest holdings make up 76% of its $306M portfolio in Q2 2021.
- Tri Locum Partners opened 14 new positions and closed 19 in Q2 2021.
- Tri Locum Partners's portfolio value fell 24% quarter-over-quarter to $306M.
Based on Tri Locum Partners's 13F filing for Q2 2021, filed 16 Aug 2021.